Quanterix (QTRX) Stock Price, News & Analysis

Company Overview

Quanterix (NASDAQ: QTRX) is a life sciences company specializing in the development and commercialization of ultra-sensitive diagnostic and research platforms. Founded in 2007 and headquartered in Billerica, Massachusetts, Quanterix pioneered the Single Molecule Array (Simoa) technology to enable the detection of proteins, nucleic acids and other biomarkers at concentrations previously undetectable by conventional methods.

The company’s flagship products include the Simoa HD-X Analyzer and the SP-X System, which leverage digital immunoassay and microarray technologies, respectively, to deliver high-throughput, precision results. Quanterix offers an expanding menu of assay kits, consumables and software, supporting applications in neuroscience, oncology, cardiology, infectious diseases and other research areas. These platforms are designed for both research use and translational applications, facilitating biomarker discovery, drug development and personalized medicine efforts.

Quanterix serves a global customer base, including pharmaceutical and biotech companies, academic research centers, contract research organizations and clinical laboratories. The company has established commercial operations and partnerships across North America, Europe and the Asia-Pacific region, providing instrument deployment, training and technical support to ensure seamless integration of its systems into diverse laboratory workflows.

Under the leadership of President and Chief Executive Officer Kevin Hrusovsky, Quanterix continues to expand its offerings through ongoing R&D investments and strategic collaborations. The company’s management team, including Chief Financial Officer Catherine Burzik and other seasoned life-sciences executives, is focused on driving innovation while maintaining robust operational and quality standards. Quanterix remains committed to advancing biomarker science and accelerating the translation of critical research into tangible clinical insights.

Key Stats

• Today's Range: $5.83 to $5.90
• 50-Day Range: $4.28 to $6.92
• 52-Week Range: $4.05 to $16.74
• Volume: 11,034 shs
• Average Volume: 608,320 shs
• Market Capitalization: $296.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.50
• Consensus Rating: Hold

Quanterix Stock Analysis - MarketRank™

Quanterix scored higher than 50% of companies evaluated by MarketBeat, and ranked 655th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Quanterix has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Quanterix has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Quanterix are expected to decrease in the coming year, from ($0.98) to ($1.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quanterix is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quanterix is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Quanterix has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.88% of the float of Quanterix has been sold short.

Short Interest Ratio / Days to Cover

Quanterix has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Quanterix has recently increased by 12.89%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quanterix does not currently pay a dividend.

Dividend Growth

Quanterix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.88% of the float of Quanterix has been sold short.

Short Interest Ratio / Days to Cover

Quanterix has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Quanterix has recently increased by 12.89%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.60

News Sentiment

Quanterix has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Quanterix this week, compared to 5 articles on an average week.

Search Interest

7 people have searched for QTRX on MarketBeat in the last 30 days.

MarketBeat Follows

6 people have added Quanterix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Quanterix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,625,444.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Quanterix is held by insiders.

Percentage Held by Institutions

86.48% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

QTRX Stock Analysis - Frequently Asked Questions

How have QTRX shares performed this year?

Quanterix's stock was trading at $10.63 at the start of the year. Since then, QTRX stock has decreased by 44.5% and is now trading at $5.90.

How were Quanterix's earnings last quarter?

Quanterix Corporation (NASDAQ:QTRX) issued its earnings results on Monday, May, 12th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.16. The business earned $30.33 million during the quarter, compared to analyst estimates of $28.27 million. Quanterix had a negative trailing twelve-month return on equity of 15.07% and a negative net margin of 36.82%.
Read the conference call transcript.

When did Quanterix IPO?

Quanterix (QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

How do I buy shares of Quanterix?

Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Quanterix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quanterix investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:QTRX
• CIK: 1503274
• Web: www.quanterix.com
• Phone: (617) 301-9400
• Fax: N/A
• Employees: 460
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Quanterix: $13.50
• High Price Target: $18.00
• Low Price Target: $8.00
• Potential Upside/Downside: +128.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.53 million
• Net Margins: -36.82%
• Pretax Margin: -37.24%
• Return on Equity: -15.07%
• Return on Assets: -12.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.29
• Quick Ratio: 7.53

Sales & Book Value

• Annual Sales: $137.42 million
• Price / Sales: 2.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.57 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 49,950,000
• Free Float: 46,507,000
• Market Cap: $294.71 million
• Optionable: Optionable
• Beta: 1.13